BACKGROUND: Although we previously demonstrated that paclitaxel and carboplatin chemotherapy (TCchem) is associated with vascular toxicities, the underlying mechanisms remain unclear. Cisplatin is known to inhibit PPARα following microvascular damage to the kidneys. The primary aim of this study was to evaluate whether TCchem induces vascular endothelial dysfunction via systemic PPARα deficiency. In addition, human umbilical vein endothelial cells (HUVECs) were used to elucidate the mechanisms responsible for TCchem-induced vascular toxicities. METHODS: This study enrolled 45 gynecological cancer patients with normal lipid profiles who underwent surgical treatment followed by TCchem. The elevated triglyceride (TG) group included patients (n = 19) who exhibited hypertriglyceridemia during TCchem, and the stable TG group (n = 15) included patients with a normal TG level. Eleven patients exhibiting hypertriglyceridemia during TCchem were administered bezafibrate (fibrate group). Endothelial dysfunction was evaluated based on flow-mediated dilation (FMD) values and serum pentraxin-3 levels measured before TCchem and immediately after the final TCchem. HUVECs were used to elucidate the biological mechanisms underlying the endothelial dysfunction induced by TCchem. RESULTS: The administration of TCchem induced hypertriglyceridemia in 66 percent of the participants, and bezafibrate reduced the serum TG levels. Meanwhile, the decrease in flow-mediated dilatation (%FMD) induced by TCchem improved following treatment with bezafibrate. The serum pentraxin-3 level increased rapidly after TCchem and decreased following bezafibrate treatment. An in vitro examination demonstrated TCchem attenuated nitric oxide production and PPARα activity in HUVECs, which was partially improved by treatment with bezafibrate. CONCLUSION: Bezafibrate prevents endothelial dysfunction induced by TCchem via TG-dependent and TG-independent mechanisms.
BACKGROUND: Although we previously demonstrated that paclitaxel and carboplatin chemotherapy (TCchem) is associated with vascular toxicities, the underlying mechanisms remain unclear. Cisplatin is known to inhibit PPARα following microvascular damage to the kidneys. The primary aim of this study was to evaluate whether TCchem induces vascular endothelial dysfunction via systemic PPARα deficiency. In addition, human umbilical vein endothelial cells (HUVECs) were used to elucidate the mechanisms responsible for TCchem-induced vascular toxicities. METHODS: This study enrolled 45 gynecological cancerpatients with normal lipid profiles who underwent surgical treatment followed by TCchem. The elevated triglyceride (TG) group included patients (n = 19) who exhibited hypertriglyceridemia during TCchem, and the stable TG group (n = 15) included patients with a normal TG level. Eleven patients exhibiting hypertriglyceridemia during TCchem were administered bezafibrate (fibrate group). Endothelial dysfunction was evaluated based on flow-mediated dilation (FMD) values and serum pentraxin-3 levels measured before TCchem and immediately after the final TCchem. HUVECs were used to elucidate the biological mechanisms underlying the endothelial dysfunction induced by TCchem. RESULTS: The administration of TCchem induced hypertriglyceridemia in 66 percent of the participants, and bezafibrate reduced the serum TG levels. Meanwhile, the decrease in flow-mediated dilatation (%FMD) induced by TCchem improved following treatment with bezafibrate. The serum pentraxin-3 level increased rapidly after TCchem and decreased following bezafibrate treatment. An in vitro examination demonstrated TCchem attenuated nitric oxide production and PPARα activity in HUVECs, which was partially improved by treatment with bezafibrate. CONCLUSION:Bezafibrate prevents endothelial dysfunction induced by TCchem via TG-dependent and TG-independent mechanisms.
Authors: Larissa Eiselein; Dennis W Wilson; Michael W Lamé; John C Rutledge Journal: Am J Physiol Heart Circ Physiol Date: 2007-01-26 Impact factor: 4.733
Authors: H S Haugnes; N Aass; S D Fosså; O Dahl; O Klepp; E A Wist; J Svartberg; T Wilsgaard; R M Bremnes Journal: Ann Oncol Date: 2006-10-23 Impact factor: 32.976
Authors: Alberto Mantovani; Cecilia Garlanda; Barbara Bottazzi; Giuseppe Peri; Andrea Doni; Yeny Martinez de la Torre; Roberto Latini Journal: Vascul Pharmacol Date: 2006-08-23 Impact factor: 5.773
Authors: F Fazzini; G Peri; A Doni; G Dell'Antonio; E Dal Cin; E Bozzolo; F D'Auria; L Praderio; G Ciboddo; M G Sabbadini; A A Manfredi; A Mantovani; P R Querini Journal: Arthritis Rheum Date: 2001-12
Authors: Limin Wang; Rajan Gill; Theresa L Pedersen; Laura J Higgins; John W Newman; John C Rutledge Journal: J Lipid Res Date: 2008-09-23 Impact factor: 5.922
Authors: Alan C Cameron; Kelly McMahon; Mark Hall; Karla B Neves; Francisco J Rios; Augusto C Montezano; Paul Welsh; Ashita Waterston; Jeff White; Patrick B Mark; Rhian M Touyz; Ninian N Lang Journal: JACC CardioOncol Date: 2020-09
Authors: Daan C H van Dorst; Stephen J H Dobbin; Karla B Neves; Joerg Herrmann; Sandra M Herrmann; Jorie Versmissen; Ron H J Mathijssen; A H Jan Danser; Ninian N Lang Journal: Circ Res Date: 2021-04-01 Impact factor: 17.367